Ultragenyx Pharmaceutical Inc (LTS:0LIF)
$ 51.134 0.686 (1.35%) Market Cap: 4.70 Bil Enterprise Value: 3.98 Bil PE Ratio: 0 PB Ratio: 10.88 GF Score: 72/100

Q2 2021 Ultragenyx Pharmaceutical Inc Earnings Call Transcript

Aug 02, 2021 / 09:00PM GMT
Release Date Price: $82.43
Operator

Good day, and thank you for standing by. Welcome to the second quarter 2021 financial results and corporate update conference call. (Operator Instructions) I would now like to hand the conference over to your first speaker today, Joshua Higa, Director of Investor Relations. Thank you. Please go ahead.

Joshua Higa
Ultragenyx Pharmaceutical Inc. - Director of IR & Corporate Communications

Good afternoon, and welcome to the Ultragenyx financial results and corporate update conference Call for the second quarter 2021. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. I am Joshua Higa, Director of Investor Relations. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Camille Bedrosian, Chief Medical Officer; and Erik Harris, Chief Commercial Officer. Mardi Dier, our Chief Financial Officer, had an unavoidable flight delay and is not able to join us on today's call.

I would like to remind investors that this call will include forward-looking statements within

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot